Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, and vision fields. These products are distributed to wholesalers, hospitals, and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.

  • Revenue in USD (TTM)85.16bn
  • Net income in USD13.33bn
  • Incorporated1887
  • Employees131.90k
  • Location
    Johnson & JohnsonOne Johnson & Johnson PlazaNEW BRUNSWICK 08933United StatesUSA
  • Phone+1 (732) 524-2455
  • Fax+1 (732) 214-0332
  • Websitehttps://www.jnj.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
JNJ:NYQ since
announced
Transaction
value
Ambrx Biopharma IncDeal completed08 Jan 202408 Jan 2024Deal completed-2.71%1.98bn
Data delayed at least 15 minutes, as of Mar 18 2024 20:10 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.